Testing a new pill for EGFR-mutated glioblastoma
Part of Cancer clinical trials.
This trial tests a new pill called ERAS-801 for people with a type of brain tumor (glioblastoma) that has a specific change in the EGFR gene. The study is for patients whose tumor has come back after treatment, or for those 70 or older who are newly diagnosed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older (or 70+ for the newly diagnosed group).
- Your tumor must have a specific change in the EGFR gene and no IDH mutation.
- You must be able to have an MRI and have recent scans showing your tumor has grown or come back.
- You must be in fairly good health overall, with normal blood counts, kidney and liver function.
- You must be able to swallow pills and not have had certain other cancer drugs recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs (ABBV-637 or ABBV-155) combined with ERAS-801 for people with recurrent glioblastoma (a type of brain cancer). It may help if your tumor has a specific genetic change (EGFR amplification) and you are having surgery to remove part of the tumor.
This Phase 1 trial studies CM93 to treat adults with recurrent (coming back) glioblastoma that has an EGFR change in the tumor. It mainly aims to see how safe CM93 is and what dose might work best, while also gathering lab information from your tumor tissue.
This trial tests a personalized immune cell treatment for a glioblastoma brain tumor that has a specific marker called EGFRvIII. The cells are made in a lab and given by infusion, and the study aims to see if they can safely target and attack the tumor.
This study is testing whether special MRI scans and blood tests can help tell the difference between true tumor growth (progression) and a treatment-related reaction called 'pseudoprogression' in people with glioblastoma. The goal is to make treatment decisions more accurate.
This trial is testing a new drug called GI-102, given alone or with pembrolizumab, before surgery for a type of brain tumor called glioblastoma or grade 4 astrocytoma. The goal is to see if these drugs can help shrink the tumor before it's removed.
This Phase 2 trial studies efinetakin alfa plus pembrolizumab for adults with recurrent glioblastoma (a fast-growing brain tumor). It aims to shrink or control the tumor and help patients live longer and better after standard treatments like surgery, radiation, and temozolomide.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.